Tarsus Pharmaceuticals, Inc. TARS
75.69
(0.27)
(0.36%)
as of 25 Sep
- Market cap
- $3.6B
- P/E
- 0.0×
Follow TARS
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | 8.11 | 13.57 | 21.58 | 11.38 | 7.58 |
P/FCF ratio |
— | — | — | — | 146.26 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | (38.15) | (32.65) | (15.06) | (93.87) | 176.99 |
P/B ratio |
— | — | — | — | 2.77 | 1.84 | 3.01 | 9.27 | 9.96 |
Price to Tangible BV |
— | — | — | — | 2.77 | 1.84 | 3.07 | 9.63 | 10.18 |
EV/Sales |
— | — | — | — | 5.11 | 6.02 | 14.38 | 10.18 | 6.81 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | 77.70 | (3.21) | (3.36) | (22.43) | (247.04) |
EV/FCF |
— | — | — | — | 92.10 | (3.18) | (3.32) | (19.90) | (98.24) |
Quick Ratio |
— | 13.29 | 70.83 | 31.22 | 14.98 | 14.30 | 6.64 | 4.21 | 3.72 |
Current Ratio |
— | 13.31 | 70.85 | 31.68 | 15.33 | 14.61 | 6.93 | 4.43 | 3.85 |
Net Debt/EBITDA |
— | 1.76 | 13.70 | 6.27 | 14.82 | 3.12 | 1.36 | 1.78 | 4.66 |
Debt/Assets |
0.00% | 0.00% | 0.17% | 0.32% | 0.33% | 8.53% | 11.23% | 19.06% | 12.89% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.15 | 0.32 | 0.21 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.33 | 0.13 | 0.07 | 0.57 | 0.96 |
Operating CF/Net income |
— | 0.90 | 0.79 | 0.79 | (0.27) | 0.79 | 0.86 | 0.72 | 0.19 |
Capex/Depreciation |
— | 0.00 | (2.36) | (1.85) | (0.97) | 0.74 | 2.89 | 2.62 | 3.21 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 35.85% | 126.92% | (33.52%) | (8.31%) | (34.53%) | (69.71%) | (54.83%) | (23.39%) | |
| — | (110.42%) | (15.39%) | (23.28%) | (7.88%) | (30.53%) | (55.09%) | (35.97%) | (14.14%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,506.21%) | 0.00% |
Return on Tangible Assets |
— | (59.68%) | (8.14%) | (16.17%) | (8.37%) | (29.44%) | (61.58%) | (41.51%) | (16.66%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.59 | 50.64 | 370.59 | 95.88 | 70.44 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 73.14% | 165.11% | 288.37% | 29.18% | 14.25% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 44.54% | 174.11% | 623.03% | 129.71% | 94.67% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 14.83% | 52.14% | 113.66% | 15.20% | 9.24% |
Graham Net Nets |
— | — | — | — | 0.35 | 0.54 | 0.32 | 0.10 | 0.09 |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | (2.93%) | (17.68%) | (23.02%) | (5.60%) | (1.98%) |
Free Cash Flow Yield |
— | — | — | — | 0.68% | (13.95%) | (20.09%) | (4.49%) | (0.92%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 2.77 | 1.05 | 0.59 | 4.87 | 10.80 |
Operating CF per Share |
— | (0.06) | (1.55) | (3.41) | 0.18 | (1.99) | (4.00) | (2.21) | (0.30) |
Capex per Share |
— | 0.00 | (0.07) | (0.07) | (0.03) | (0.02) | (0.19) | (0.17) | (0.24) |
Free Cash Flow per Share |
— | (0.06) | (1.63) | (3.48) | 0.15 | (2.01) | (4.19) | (2.38) | (0.53) |
Cash per Share |
— | 0.12 | 24.53 | 27.09 | 8.36 | 8.82 | 7.74 | 7.75 | 10.00 |
Shareholders Equity per Share |
— | 0.11 | 24.29 | 26.74 | 8.11 | 7.84 | 6.70 | 5.97 | 8.22 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.11 | 24.29 | 26.74 | 8.11 | 7.84 | 6.70 | 5.97 | 8.22 |
Free Cash Flow |
— | (1.18) | (3.85) | (21.59) | 3.16 | (49.54) | (122.99) | (89.59) | (22.31) |
Working Capital |
— | 2.20 | 57.21 | 165.27 | 164.47 | 209.95 | 219.20 | 276.09 | 387.09 |
Capital Expenditures |
— | (0.01) | (0.17) | (0.46) | (0.59) | (0.51) | (5.50) | (6.57) | (9.86) |
Net Current Asset Value |
— | 2.20 | 57.11 | 164.66 | 163.78 | 190.41 | 187.63 | 204.25 | 304.05 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.01 | 0.02 | 0.32 | 0.04 | 0.02 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | (24.25%) | (240.51%) | (778.89%) | (63.16%) | (14.72%) |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.17 | 0.48 | 0.45 | 0.80 | (0.71) | (1.29) | (1.08) | (0.26) |
Cash ROIC |
— | (25.93%) | (3.31%) | (6.48%) | 0.88% | (11.64%) | (26.19%) | (14.52%) | (2.89%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 1,018.34 | 14.05 | 1.64 | 5.56 | 6.68 |
Accounts Payable Turnover |
— | 0.00 | 0.21 | 0.10 | 0.32 | 0.10 | 0.09 | 0.77 | 2.38 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.48 | 8.78 |
Average Days of Payables |
— | 63,875.00 | 2,564.86 | 6,449.82 | 1,526.84 | 3,787.59 | 5,428.26 | 268.04 | 194.93 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 711.90 | 74.56 | 52.01 |
Average Receivables |
— | 0.02 | 0.02 | 0.03 | 0.06 | 1.84 | 10.65 | 32.89 | 67.58 |
Average Payables |
— | 0.32 | 0.35 | 2.43 | 6.51 | 9.30 | 16.80 | 16.56 | 12.90 |
Average Inventory |
— | — | — | — | — | — | — | 2.86 | 3.50 |
Average Assets |
— | 1.19 | 30.35 | 115.14 | 175.44 | 203.39 | 246.68 | 321.24 | 469.57 |
Average Common Equity |
— | (3.68) | (3.68) | 79.99 | 166.36 | 179.82 | 194.94 | 210.76 | 283.98 |
Columns are period end dates